Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention.
about
Eating disorders in schizophrenia: implications for research and managementFrom the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinaseIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsMonitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patientsThe pulsatility volume index: an indicator of cerebrovascular compliance based on fast magnetic resonance imaging of cardiac and respiratory pulsatility.The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk.High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias.Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSex differences in the combined effect of chronic stress with impaired vascular endothelium functioning and the development of early atherosclerosis: the Cardiovascular Risk in Young Finns study.Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.A genetic risk variant for myocardial infarction on chromosome 6p24 is associated with impaired central hemodynamic indexes.Arterial stiffness in patients with deep and lobar intracerebral hemorrhageWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Metabolic Abnormality and Sleep Disturbance are Associated with Clinical Severity of Patients with Schizophrenia.Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 miceBetter management of cardiovascular diseases by pulse wave velocity: combining clinical practice with clinical research using evidence-based medicine.Is depression an inflammatory disorder?Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype.Noninvasive assessment of preclinical atherosclerosis.Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia.Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients.Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Mechanisms of arterial remodeling: lessons from genetic diseases.Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial.Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trialGenome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.Dopamine 2 Receptor Genes Are Associated with Raised Blood Glucose in Schizophrenia.Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.Guideline-concordant antipsychotic use and mortality in schizophrenia.Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem.Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria.Off-label use of atypical antipsychotics in personality disorders.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.Physical complications in early clozapine treatment: a case report and implications for safe monitoring.Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine
P2860
Q21284525-4C5FC60E-0A48-469E-ACAD-B1849632AB06Q24685521-51A8C6EE-33C6-4398-BCCC-983A93AA5DA4Q27027832-9C07F37F-95B2-4F5C-BD2E-D55357804BB7Q28275063-34ACD19A-35EB-4AA3-9B42-342E731032F6Q30356554-B4BF3B55-82DA-4482-AB57-2601FB9214B0Q30837072-C226803A-A442-4D03-8E3D-D2876BDA54B6Q31147850-5A8C2228-CFB6-4CC4-9A90-9700806710CEQ33302249-BC50A6BF-CD30-431B-96B6-B225AA0E9FD8Q33518314-8B28C230-BC6B-4325-9275-4493DEF0E5DBQ33566124-3C6A6693-96F2-42A3-AF1E-B766EE427431Q33630821-DFCB04C6-C6A9-497E-986A-9E0CD3C87EC2Q33707663-864CFB5D-AAF3-4111-A2B8-48FC2ED20BE3Q33942644-45D05093-759C-4A0F-8C44-8D95120DB0D2Q34024421-FB8C27DB-28ED-4C42-9AB6-AF4F68AE0CC7Q34357551-0C653C52-FEFD-4313-8A91-39302A9CA65CQ34640811-B629DB75-61FF-4D0E-A194-798601CB662AQ34691850-264207A6-FFCC-4547-B4AF-E8811118524DQ34985850-51DD2FE9-55A5-4929-AD05-CCA8DFDF51E4Q35758407-4E12201A-7057-4F6F-A484-8AD6952AE299Q35774501-4885ACD8-5160-437A-82E1-AE37FD701A88Q35844191-F94D18C3-AD61-4BC9-B836-EE5AB0484B8AQ36012908-E6F59DAB-9060-40AE-87B5-EC88AA829503Q36241602-C6FE546E-3159-42CC-A3DA-54E90F7B86ECQ36303695-734AE7DA-6B54-485B-84F0-584A8FA9ED9BQ36371905-2607E734-929C-4A88-9F4A-DB9048217BC6Q36377890-BF46D044-5097-4C6A-B4F5-78EDF557E1D4Q36463642-F96D67D5-44E9-4DF9-9E9E-5D372E1F5A4AQ36564507-F324CC4F-FC5C-4185-96D6-E5A3D2FDBDF9Q36723396-700C94DC-FAAB-48CE-A751-1B751F84767DQ36817242-FA313778-1A93-469C-B395-F711CDDAED24Q36826582-A1E53E4D-9D2A-4F23-83C1-6BCF1DBF4FEEQ36980867-6B267810-99E1-4F58-804B-764FD5E7980CQ37131022-BA916C50-9363-403D-837D-1324EA165655Q37137008-449473F7-44A0-4AA5-996C-0B1047E9CA59Q37598227-8BE94310-16FB-4D64-8F0C-958BF6488BD6Q37681620-A6B93BA5-2D72-46A8-B24D-527011A7735CQ37935806-5BC9B4DE-4CDE-43B5-824C-781AED0A9FC9Q37947095-8E7190EF-2E07-4AF2-BBBB-00705AC8E24FQ38132160-3EF7D9F3-D956-4BC6-9570-B95757FE6464Q38132163-EF6772B0-5A50-4E3C-99A5-200CB54CCFCE
P2860
Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Arterial stiffness and stroke ...... cations for stroke prevention.
@ast
Arterial stiffness and stroke ...... cations for stroke prevention.
@en
type
label
Arterial stiffness and stroke ...... cations for stroke prevention.
@ast
Arterial stiffness and stroke ...... cations for stroke prevention.
@en
prefLabel
Arterial stiffness and stroke ...... cations for stroke prevention.
@ast
Arterial stiffness and stroke ...... cations for stroke prevention.
@en
P1433
P1476
Arterial stiffness and stroke ...... cations for stroke prevention.
@en
P2093
Stéphane Laurent
P356
10.2165/00023210-200519010-00001
P577
2005-01-01T00:00:00Z
P6179
1051267017